The mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy or other treatment modalities.

Condition	Intervention	Phase
Mucopolysaccharidosis I Hurler''''s Syndrome Hurler-Scheie Syndrome Scheie Syndrome	Procedure: Aldurazyme (Recombinant Human Alpha-L-Iduronidase)	Phase IV

Further Study Details: 

Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• All patients with a confirmed diagnosis of MPS I are eligible for inclusion:

confirmed diagnosis is defined as: documented biochemical evidence of a deficiency in a-L-iduronidase enzyme activity and/or mutation and/or mutations(s) in the gene coding for a-L-iduronidase, or measurable clinical signs and symptoms of MPS I

• For all patients there should be a completed patient authorization form

Exclusion Criteria:

• no exclusion criteria in this Registry

Please refer to this study by ClinicalTrials.gov identifier  NCT00144794

Medical Information      800-745-4447    medinfo@genzyme.com
Medical Information      617-252-7832    medinfo@genzyme.com

California
      Children''''s Hospital Los Angeles, Los Angeles,  California,  90027,  United States; Recruiting
Minnesota
      Gene Therapy Center, Minneapolis,  Minnesota,  55455,  United States; Recruiting

Study ID Numbers:  MPS I Registry
Last Updated:  September 2, 2005
Record first received:  September 2, 2005
ClinicalTrials.gov Identifier:  NCT00144794
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-06